Publication date: September 2024.

Determining the exact number of patients treated with CAR-T therapy worldwide is challenging, given the widespread adoption of this advanced treatment across various countries. Nevertheless, we can offer some insights based on data collected from multiple sources, segmented by region:

  1. Global Overview:
    • Over 22,000 blood cancer patients have received CAR-T therapy as of 2022.
  2. United States:
    • A 2023 study estimated that 3.9% of patients with advanced or metastatic cancers were eligible for CAR-T therapies.
  3. Israel:
    • Sheba Medical Center has administered CAR-T therapy to over 350 patients since 2015.
    • Hadassah Hospital has performed more than 60 CAR-T therapy procedures.
  4. European Union:
    • A 2020 analysis in the four largest EU countries (France, Germany, Spain, Italy) revealed that less than 50% of eligible diffuse large B-cell lymphoma (DLBCL) patients received CAR-T therapy. The breakdown by country in 2020 was:
    • France: 71%
    • Germany: 63%
    • Spain: 55%
    • Italy: 29%
  5. Germany:
    • CAR-T cell therapy is available in 26 clinics, with over 300 patients treated.
  6. Saudi Arabia:
    • King Faisal Specialist Hospital has treated over 100 patients with advanced CAR-T cell therapy.
  7. China:
    • The numbers for China are missing from the available data.

While these figures do not provide a comprehensive global total, they offer a glimpse into the prevalence of CAR-T therapy use in several key regions. The actual number worldwide is likely significantly higher, considering the growing number of facilities offering this treatment and its expanding approval for various conditions.